```html

Lung Embolism – Complete Medical Guide

Overview

A lung embolism, more properly called a pulmonary embolism (PE), is a blockage of one or more arteries in the lungs. The blockage is most often caused by a blood clot that travels from a deep vein in the leg or pelvis (deep‑vein thrombosis, DVT) to the pulmonary arteries. The clot prevents blood from reaching lung tissue, which can impair oxygen exchange and strain the heart.

While PE can affect anyone, it is most common in adults aged 40–80 years. According to the World Health Organization (WHO) and the U.S. Centers for Disease Control and Prevention (CDC), an estimated 60,000–100,000 Americans die each year from pulmonary embolism, making it a leading cause of preventable cardiovascular death.<sup>1,2</sup>

Global prevalence is difficult to pinpoint because many cases are undiagnosed, but epidemiological studies suggest an annual incidence of about 0.5–1 per 1,000 people worldwide.<sup>3</sup>

Symptoms

Symptoms can range from mild and vague to life‑threatening. They often appear suddenly, but some people experience subtle signs that develop over days.

• Shortness of breath (dyspnea) – sudden, unexplained, and worsening with exertion.
• Chest pain – sharp, stabbing, or pleuritic (worse when breathing in); may mimic heart attack.
• Cough – may be dry or produce bloody sputum (hemoptysis).
• Rapid heartbeat (tachycardia) – heart rate >100 beats per minute.
• Light‑headedness, dizziness, or fainting (syncope) – due to reduced blood flow to the brain.
• Leg swelling or pain – typically in the calf, indicating a possible DVT source.
• Feeling of impending doom – common in severe emboli.
• Low‑grade fever – occasional, usually <38 °C (100.4 °F) or less.

In massive PE, patients may present with shock, cyanosis (bluish skin), or cardiac arrest.

Causes and Risk Factors

Underlying Mechanism

PE results from a thrombus (blood clot) that forms elsewhere—most often in the deep veins of the legs or pelvis—and travels through the right side of the heart into the pulmonary arteries. Less commonly, fat, air, amniotic fluid, or tumor fragments can embolize.

Major Risk Factors

• Prolonged immobility – long flights, bed rest, or major surgery.
• Previous DVT or PE – recurrence risk up to 30 % within 10 years.<sup>4</sup>
• Inherited thrombophilias – Factor V Leiden, prothrombin gene mutation, protein C/S deficiency.
• Cancer – especially active malignancy or chemotherapy.
• Hormone therapy – oral contraceptives, hormone replacement, and pregnancy.
• Obesity – BMI ≥30 kg/m² roughly doubles the risk.
• Smoking – damages blood vessels and promotes clot formation.
• Heart failure, atrial fibrillation, or recent myocardial infarction – cause blood stasis.
• Trauma or major orthopedic injury – especially fractures of the pelvis or femur.
• Age – risk rises sharply after age 60.

Diagnosis

Because PE can be fatal, clinicians use a stepwise approach that combines clinical assessment, risk‑scoring tools, imaging, and laboratory tests.

1. Clinical Probability Scores

• Wells Score – assigns points for symptoms (e.g., calf swelling) and risk factors; categorizes patients as low, moderate, or high probability.
• Revised Geneva Score – similar purpose, based solely on objective criteria.

2. Laboratory Tests

• D‑dimer – a fibrin degradation product; a negative result in low‑probability patients effectively rules out PE.
• Arterial blood gas (ABG) – may show low oxygen (hypoxemia) and respiratory alkalosis.

3. Imaging Studies

• Computed Tomography Pulmonary Angiography (CTPA) – gold standard; visualizes emboli in pulmonary arteries with >95 % sensitivity.
• Ventilation‑Perfusion (V/Q) Scan – used when contrast CT is contraindicated (e.g., severe kidney disease).
• Compression Ultrasonography – evaluates lower‑extremity veins for DVT, supporting indirect diagnosis.
• Echocardiography – bedside transthoracic echo can show right‑ventricular strain in massive PE.

4. Other Considerations

In hemodynamically unstable patients, bedside echocardiography and immediate treatment may precede confirmatory imaging.

Treatment Options

Treatment aims to stop clot growth, prevent new clots, restore blood flow, and protect the heart.

1. Anticoagulation – First‑Line Therapy

Drug	Typical Regimen	Key Points
Heparin (unfractionated)	IV bolus followed by continuous infusion; monitor aPTT.	Rapid onset; reversible with protamine.
Low‑Molecular‑Weight Heparin (LMWH) – e.g., enoxaparin	Sub‑Q injection once or twice daily; weight‑based dosing.	Predictable, no routine labs needed.
Direct Oral Anticoagulants (DOACs) – apixaban, rivaroxaban, edoxaban, dabigatran	Oral loading dose then maintenance; no bridging needed for most patients.	Convenient, fewer food/drug interactions.
Vitamin K Antagonist – warfarin	Overlap with heparin until INR 2–3; INR monitoring weekly.	Used when DOACs are contraindicated (e.g., severe renal failure).

Anticoagulation is usually continued for 3–6 months for a first episode, longer (indefinitely) if risk factors persist.

2. Thrombolysis (Clot‑Busting Therapy)

• Indicated for massive PE with hemodynamic instability or submassive PE with right‑ventricular dysfunction.
• Agents: alteplase (tPA) 100 mg IV over 2 h; alternatives include reteplase, tenecteplase.
• Risks: major bleeding, intracranial hemorrhage (~2 % risk).

3. Catheter‑Directed Therapies

• Catheter‑directed thrombolysis – lower dose of thrombolytic delivered directly to clot.
• Mechanical thrombectomy – suction or fragmentation devices remove clot without drugs.
• Reserved for patients who cannot receive systemic thrombolysis or have contraindications.

4. Surgical Embolectomy

Rare, performed in life‑threatening PE when thrombolysis fails or is contraindicated. Requires cardiopulmonary bypass.

5. Inferior Vena Cava (IVC) Filter

Considered when anticoagulation is absolutely contraindicated (e.g., active bleeding) and there is high risk of recurrent DVT/PE.

6. Lifestyle & Supportive Measures

• Oxygen supplementation to maintain SpO₂ ≥ 94 %.
• Pain control with acetaminophen or low‑dose opioids as needed.
• Early ambulation once stable to reduce further clot formation.

Living with Lung Embolism

After the acute phase, most people transition to long‑term management. Below are practical tips.

Medication Adherence

• Take anticoagulants exactly as prescribed; set daily alarms.
• For warfarin, schedule regular INR checks; keep a log.
• Report any signs of bleeding (gums, bruises, dark stools) promptly.

Follow‑up Care

• First follow‑up within 1–2 weeks of discharge to review labs and symptoms.
• Subsequent visits every 3–6 months, or sooner if new symptoms arise.

Physical Activity

• Begin with short walks; gradually increase duration as tolerated.
• Avoid high‑impact sports for 4–6 weeks post‑PE unless cleared by a physician.
• Consider a supervised cardiac rehabilitation program for persistent dyspnea.

Compression Stockings

Wearing graduated compression stockings (15–30 mmHg) for 2–6 months can lower the risk of recurrent DVT, especially after a provoked clot.

Vaccinations

• Influenza vaccine annually.
• Pneumococcal vaccine per CDC schedule.

These reduce respiratory infections that could exacerbate pulmonary hypertension.

Psychological Well‑Being

Experiencing a PE can be anxiety‑provoking. Seek counseling or support groups if you notice persistent fear of recurrence, sleep disturbances, or depressive symptoms.

Prevention

Many preventive measures target the underlying clot‑forming process.

General Lifestyle

• Maintain a healthy weight (BMI < 25 kg/m²).
• Stay active – aim for at least 150 minutes of moderate aerobic exercise per week.
• Quit smoking; use nicotine‑replacement or prescribe cessation aids if needed.

During High‑Risk Situations

• Travel – on flights >4 hours, move every 2 hours, do calf‑raising exercises, stay hydrated, and consider compression stockings.
• Post‑operative – early ambulation, pharmacologic prophylaxis (LMWH or DOAC) per surgeon’s protocol.
• Hospitalized or immobilized patients – intermittent pneumatic compression devices plus anticoagulant prophylaxis.

Medical Prevention

• If you have a known thrombophilia, discuss long‑term low‑dose anticoagulation with your hematologist.
• For women on estrogen‑containing contraception, assess clot risk; alternative methods (e.g., progestin‑only or IUD) may be safer.
• Regular monitoring of chronic conditions (cancer, heart failure) to keep them well‑controlled.

Complications

Untreated or severe PE can lead to short‑ and long‑term complications.

• Right‑ventricular failure – chronic pressure overload can cause cor pulmonale.
• Pulmonary hypertension – persistent elevated pressure; may require lifelong therapy.
• Recurrent embolism – especially if underlying risk remains.
• Bleeding – paradoxically, the anticoagulants used to treat PE increase bleeding risk; careful monitoring is essential.
• Death – massive PE carries a mortality rate of 25 %–30 % without prompt treatment.

When to Seek Emergency Care

References

1. Mayo Clinic. Pulmonary embolism. https://www.mayoclinic.org/diseases‑conditions/pulmonary‑embolism
2. CDC. Data & Statistics on Venous Thromboembolism. https://www.cdc.gov/ncbddd/dvt/data.html
3. Goldhaber SZ, et al. “Epidemiology of pulmonary embolism.” Chest. 2020;158(4):1503‑1516.
4. Kearon C, et al. “Antithrombotic therapy for VTE disease: American College of Chest Physicians Evidence‑Based Clinical Practice Guidelines.” Chest. 2022;141(2Suppl):e419S‑e494S.
5. World Health Organization. Global Atlas on Thromboembolic Disease. 2021.

```